Trial Profile

A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Mar 2026 According to an Arcutis Biotherapeutics media release, data from the trial were presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.
18 Mar 2026 According to an Arcutis Biotherapeutics media release, data from the trial will be presented during the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31 in Denver.
17 Sep 2025 Results presented in an Arcutis Biotherapeutics media.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com